The value of contrast-enhanced ultrasound in percutaneous biopsy of retroperitoneal masses

Ehsan Safai Zadeh,Mathis Görg,Christian Görg,Helmut Prosch,Corinna Trenker,Christina Carolin Westhoff,Christoph F. Dietrich,Nils Raab,Amjad Alhyari,Katharina Huber,Svitlana Pochepnia,Michael Weber,Hajo Findeisen

DOI: https://doi.org/10.1055/a-2282-2353

2024-04-09

Ultraschall in der Medizin - European Journal of Ultrasound

Abstract:Purpose To evaluate the diagnostic yield of contrast-enhanced ultrasound (CEUS)-guided biopsy of retroperitoneal masses (RMs). Materials and Methods Between 2006 and 2023, 87 patients presented at our US center for biopsy of an RM. In all biopsies, CEUS was performed prior to the intervention. The technical success rate of biopsy, the presence of diagnostic tissue in solid tumor biopsy samples, the accuracy of the biopsy and the occurrence of post-interventional complications were evaluated. Results A US-guided biopsy could be conducted in 84/87 cases (96.6%). In 3/87 cases (3.4%), US-guided biopsy was impossible because the planned needle path was obstructed by vital structures. Of 84 lesions, 80 (95.2%) were solid lesions, and 4 (4.8%) were lesions containing fluid. In all solid tumors, 80/80 (100%), diagnostic vital tissue was successfully obtained. CEUS-guided biopsy showed a sensitivity of 93.2%, a specificity of 100%, a positive predictive value of 100%, a negative predictive value of 72.2%, and a diagnostic accuracy of 94.2% for the differentiation between malignant and benign RMs. In one of the 84 cases (1.2%), there was a complication of postinterventional abdominal pain. Conclusion Percutaneous CEUS-guided biopsy is a safe procedure with a high diagnostic yield and a low complication rate. Ziel Evaluierung des diagnostischen Stellenwerts der CEUS-geführten Biopsie (CEUS: kontrastverstärkter Ultraschall) von retroperitonealen Massen (RMs). Material und Methoden Zwischen 2006 und 2023 stellten sich 87 Patienten in unserem Ultraschallzentrum zur Biopsie einer RM vor. Bei allen Biopsien wurde vor dem Eingriff eine CEUS durchgeführt. Die technische Erfolgsrate der Biopsie, das Vorhandensein diagnostisch vitalen Gewebes in den Biopsieproben bei soliden Tumoren, die Treffsicherheit der Biopsie und das Auftreten von Komplikationen nach der Intervention wurden evaluiert. Ergebnisse Eine ultraschallgeführte Biopsie konnte in 84 von 87 Fällen (96,6%) durchgeführt werden. In 3 von 87 Fällen (3,4%) war eine ultraschallgeführte Biopsie aufgrund von vorgelagerten lebenswichtigen Strukturen auf dem geplanten Punktionsweg nicht möglich. Von 84 Läsionen waren 80 (95,2%) solide Läsionen und 4 (4,8%) flüssigkeitsgefüllte Läsionen. Bei allen soliden Tumoren (80/80; 100%) wurde erfolgreich diagnostisch vitales Gewebe gewonnen. Die CEUS-geführte Biopsie zeigte eine Sensitivität von 93,2%, eine Spezifität von 100%, einen positiven prädiktiven Wert von 100%, einen negativen prädiktiven Wert von 72,2% und eine diagnostische Treffsicherheit von 94,2% für die Unterscheidung zwischen malignen und benignen RMs. In einem Fall (1,2%) kam es zu einer Komplikation in Form von postinterventionellen abdominellen Schmerzen. Schlussfolgerung Die perkutane CEUS-geführte Biopsie stellt ein sicheres Verfahren dar – mit hoher diagnostischer Treffsicherheit und geringer Komplikationsrate. Received: 21 December 2023 Accepted after revision: 01 March 2024 Article published online: 08 April 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

radiology, nuclear medicine & medical imaging,acoustics

What problem does this paper attempt to address?

This paper aims to evaluate the diagnostic value of percutaneous biopsy under contrast-enhanced ultrasound (CEUS) guidance in diagnosing retroperitoneal masses (RMs). Specifically, the researchers hope to verify through this study whether biopsy under CEUS guidance can improve diagnostic accuracy and reduce the incidence of complications.

The background of the paper points out that retroperitoneal masses may include various primary and secondary pathologies, ranging from benign to malignant mesenchymal tumors, lymphomas, metastatic cancers, germ cell tumors, and inflammatory processes. Since these masses often exhibit nonspecific characteristics in imaging examinations such as conventional ultrasound (B-US), computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT), histological examination is required to determine the final diagnosis. The use of contrast-enhanced ultrasound technology (CEUS) can improve the visualization of lesions, helping to identify and avoid necrotic or non-viable tumor tissue, thereby improving the diagnostic accuracy of the biopsy.

The study retrospectively analyzed data from 87 patients between 2006 and 2023 to evaluate the technical success rate of CEUS-guided biopsy, the presence of viable tissue in diagnostic samples, the accuracy of the biopsy, and the incidence of postoperative complications. The results showed that CEUS-guided biopsy had a high technical success rate (96.6%) and successfully obtained diagnostic samples in all solid tumors. Additionally, the sensitivity of CEUS-guided biopsy in distinguishing malignant from benign retroperitoneal masses was 93.2%, specificity was 100%, positive predictive value was 100%, negative predictive value was 72.2%, diagnostic accuracy was 94.2%, and the complication rate was low (1.2%).

In conclusion, the study suggests that percutaneous biopsy under CEUS guidance is a safe and efficient diagnostic method, particularly suitable for the diagnosis of retroperitoneal masses, with high diagnostic value and low risk of complications.